SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000030
Filing Date
2021-02-25
Accepted
2021-02-25 16:15:14
Documents
17
Period of Report
2021-02-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210224.htm   iXBRL 8-K 41954
2 EX-1.1 adms8-k022021ex11.htm EX-1.1 264484
3 EX-5.1 adms8-k022021ex51.htm EX-5.1 10282
9 image21.jpg GRAPHIC 10498
  Complete submission text file 0001328143-21-000030.txt   532344

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210224.xsd EX-101.SCH 2423
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20210224_cal.xml EX-101.CAL 710
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20210224_def.xml EX-101.DEF 1643
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210224_lab.xml EX-101.LAB 26042
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210224_pre.xml EX-101.PRE 14071
10 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210224_htm.xml XML 10978
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 21680513
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences